"The surest method of lowering healthcare costs in America is preventing the need for treatment. Having access to a safe and effective OTC alternative such as AminoActiv empowers former NSAID users not only to lower their medical costs, but also to improve their quality of life," said Faulkner.
The Affordable Care Act of 2010 emphasizes prevention as essential to reeling in excessive healthcare costs. As such, the consumer's share of out-of-pocket costs for chronic care may noticeably increase. NSAID alternatives have the potential to reduce these costs dramatically.
"With almost 33 million people regularly using NSAIDs for pain and inflammation, the shift to safe, non-toxic alternatives will save our healthcare system billions annually," commented Faulkner.
AminoActiv is currently available as both a capsule and a topical cream. AminoActiv users report relief from a variety of pain conditions, including arthritis pain, joint & back pain, plantar fasciitis, and muscle strains. AminoActiv can be purchased at the online store or locally at select locations ( http://aminoactiv.com/where-to-find-aminoactiv-locally/)."As knowledge grows about the high cost of NSAIDs and their side effects, the demand for alternatives will only increase," concluded Faulkner. "AminoActiv's safety and performance record argues for its use as a first-line treatment for pain and inflammation." To request more information about the research study, contact Mark Faulkner at 855-442-6466. About Vireo Systems, Inc. Taking inspiration from one of the Latin words for "health," Vireo Systems, Inc. is the manufacturer of a number of nutraceuticals and health promotion products including AminoActiv, the #1 alternative to ibuprofen and NSAIDs. Vireo was founded in 2002 as part of a project with several university-based researchers, and today, the company's products deliver safe, effective relief for inflammation and pain. Vireo meets industry-standard good manufacturing practices as expected by the FDA, and AminoActiv safety and toxicity data have been reviewed and accepted by the FDA.